Published: May 17, 2021
International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease
Clene anticipates the expansion of disease indications for CNM-Au8 beyond amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis
SALT LAKE CITY, May 17, 2021 (GLOBE NEWSWIRE)
Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, received a Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine (NAM) to accelerate the preclinical development of CNM-Au8, a bioenergetic nanocatalyst, for treatment of neuronal aging-related deficits and Alzheimer’s disease. The Healthy Longevity Global Competition was founded in 2019
Voorbij de witte mannen – De Groene Amsterdammer
groene.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from groene.nl Daily Mail and Mail on Sunday newspapers.
Ultima ora local: Arhitecti suceveni prezenti la Bienala de Arhitectura de la Venetia editia a XVII a » Monitorul de Suceava
monitorulsv.ro - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from monitorulsv.ro Daily Mail and Mail on Sunday newspapers.
ImagesBazaar/Getty Images
Signs of Parkinson’s disease could be detected in the nose years before people develop more obvious symptoms of the condition.
The finding could lead to the development of a nasal swab test for the disorder, similar to ones used for coronavirus testing, and may shed light on its causes, says Werner Poewe at the Medical University of Innsbruck in Austria.
Parkinson’s disease is a condition involving tremors and difficulties in moving that usually starts in later life. It is caused by the death of brain … Continue reading Subscribe now for unlimited access
App + Web